17 - 18 May, 2017 | London, UK

Shanade Dunn

Postdoctoral Fellow
Wellcome Trust Sanger Institute in collaboration with AstraZeneca

1:50 PM Using CRISPR screening to identify the genes involved in resistance and sensitisation to PI3K pathway inhibitors in breast cancer

  • Understand how CRISPR screening can be used to identify resistant and sensitive genes related to the P13k pathway
  • Learn what the screening data has shown and how the project is already achieving success
  • Plan your CRISPR screening technique around the challenges uncovered and overcome in this project

Check out the incredible speaker line-up to see who will be joining Shanade .

Download The Latest Agenda